Cholinesterase Inhibitors Beneficial for Dementia With Lewy Bodies
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 28, 2024 -- Cholinesterase inhibitors (ChEIs) are beneficial for patients with dementia with Lewy bodies (DLB), according to a study published online Aug. 23 in Alzheimer's & Dementia.
Hong Xu, M.D., Ph.D., from the Center for Alzheimer Research at the Karolinska Institutet in Stockholm, and colleagues examined the impact of ChEIs and memantine on cognition, major adverse cardiovascular events, and mortality in patients with DLB. Data were included from 1,095 incident DLB patients. The effect of initiating a ChEI or memantine within 90 days of DLB diagnosis and nonuse was assessed.
The researchers found that compared with memantine and nonuse, use of ChEIs significantly slowed cognitive decline at follow-ups (Mini-Mental State Examination, −0.39 points per year versus −2.49 and −2.50 points per year, respectively). No difference in major adverse cardiovascular events was seen for the treatment groups. There was an association observed for ChEI use with a lower risk for death in the first year after DLB diagnosis (adjusted hazard ratio, 0.66).
"Future studies are needed to better elucidate these mechanisms," the authors write. "Clinical trials should be conducted for longer than two years of follow-up to assess long-term outcomes such as cardiovascular events and mortality."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
MONDAY, July 21, 2025 -- For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.